Controlled-release zolpidem improves freezing of gait and levodopa-induced dyskinesias in a patient with Parkinson’s disease.
Objective: To report a patient with Parkinson’s disease with freezing of gait and levodopa-induced dyskinesias who improved with zolpidem. Background: A 57-year-old man developed Parkinson’s…Impacts of mutations in Parkinson’s disease-related genes on telomere maintenance
Objective: To investigate the correlation between telomere length (TL) and Parkinson’s disease (PD), and whether the change in telomere biology participates in PD pathogenesis. Background:…Tremor in patients with chronic inflammatory demyelinating polyneuropathy: prevalence and severity
Objective: To determine prevalence and severity of tremor in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Background: Tremor is an underrecognized and possibly disabling symptom…Epigenetic clock acceleration is linked to earlier onset and phenoconvertion of Rapid-eye-movement sleep behavior disorder
Objective: In the current study, we aim to evaluate whether Rapid-eye-movement sleep behavior disorder (RBD) age-at-onset and age-at-phenoconversion are associated with DNA methylation-age acceleration (DNAm-AA).…Validation of the EQ-5D-3L in Spinocerebellar Ataxia (SCA)
Objective: Our study aims to assess the acceptability, validity and responsiveness of the EQ-5D-3L in SCA types 1, 2, 3 and 6. Background: Although health-related…Genetic polymorphisms associated with nigrostriatal dopaminergic depletion as measured with [I123]-FP-CIT SPECT in Parkinson’s disease
Objective: To conduct a genome-wide association study (GWAS) of striatal [I123]-FP-CIT SPECT signal as endophenotype to explore possible associations between genetic background and nigrostriatal dopaminergic…The spatial and spectral organization of thalamo-cortical connectivity in patients with essential tremor
Objective: To identify cortical areas coupled to the ventral intermediate nucleus of the thalamus (VIM) in patients with essential tremor (ET). Background: ET is a…Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.
Objective: To determine the safety of oral nicotinamide riboside (NR) 3000 mg daily for 4 weeks in Parkinson’s disease (PD). Secondary objectives: To assess NRs…Heart-rate variability as a new marker for freezing predisposition in Parkinson’s disease
Objective: We aim to investigate for the first time whether it is possible to detect a predisposition for upcoming Freezing of Gait (FoG) events from…
- « Previous Page
- 1
- …
- 147
- 148
- 149
- 150
- 151
- …
- 1374
- Next Page »